本帖最后由 老马 于 2012-1-13 21:20 编辑
( i) a: F" M6 B; z) w3 {" s& [6 Y
爱必妥和阿瓦斯丁的比较
4 ]! M4 L: K7 u3 O0 w8 l
- m |% y! c+ W8 W' i$ C5 C
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 v' z! V4 h" b1 G5 ?+ l
" S J( C3 f- J+ x
: k/ E9 l$ L, g7 ohttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
4 N9 Y+ r" Y( F% h$ W* B& w==================================================
$ [; j! y. i4 A% ?Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
# ]8 I0 k* r7 o, yPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point., d- K5 k: p. t T9 [" F5 B/ d
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
: E: e& J% f1 b% K
|